MedTrace Logo

Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.

NCT00333866 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 747

Last updated 2021-02-11

Study results available
· View outcomes & findings →

Summary

This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DRUG

pregabalin

600mg/day

DRUG

pregabalin

450mg/day

DRUG

pregabalin

300mg/day

DRUG

placebo

placebo

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • Australia
  • Canada
  • Denmark
  • France
  • Germany
  • India
  • Italy
  • Mexico
  • Netherlands
  • Portugal
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom
  • Venezuela

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00333866 on ClinicalTrials.gov